Home » Stocks » BLRX

BioLineRx Ltd. (BLRX)

Stock Price: $2.90 USD -0.18 (-5.84%)
Updated Mar 3, 2021 4:00 PM EST - Market closed
Market Cap 133.16M
Revenue (ttm) n/a
Net Income (ttm) -30.02M
Shares Out 252.84M
EPS (ttm) -1.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 3
Last Price $2.90
Previous Close $3.08
Change ($) -0.18
Change (%) -5.84%
Day's Open 3.13
Day's Range 2.83 - 3.13
Day's Volume 1,251,486
52-Week Range 1.06 - 4.23

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
PRNewsWire - 1 week ago

TEL AVIV, Israel, Feb. 23, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial res...

Seeking Alpha - 1 month ago

BioLineRx Ltd. is a late-stage biopharmaceutical company focused on oncology with 2 multi-indication candidates (Phase 3 and Phase 1/2a) and 1 approved product. BioLineRx's pipeline and produc...

PRNewsWire - 1 month ago

TEL AVIV, Israel, Jan. 22, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced the closing of ...

PRNewsWire - 1 month ago

TEL AVIV, Israel, Jan. 20, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that due to dem...

PRNewsWire - 1 month ago

TEL AVIV, Israel, Jan. 19, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has ent...

Benzinga - 2 months ago

Esperion Therapeutics (NASDAQ: ESPR) shares are trading higher on Wednesday after the company announced Swiss Approval for the first-in-class cholesterol-lowering treatment NILEMDO and its Com...

Other stocks mentioned: ESPR, HTBX
PRNewsWire - 2 months ago

TEL AVIV, Israel, Dec. 16, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical Company focused on oncology, today announced results from th...

Seeking Alpha - 3 months ago

BioLineRx's (BLRX) CEO Phil Serlin on Q3 2020 Results - Earnings Call Transcript

PRNewsWire - 3 months ago

TEL AVIV, Israel, Nov. 23, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial res...

InvestorPlace - 4 months ago

BLRX stock is blasting off on Friday morning after the company reported strong results from a Phase-3 trial for one of its cancer treatments. The post BioLineRX News: Why BLRX Stock Is Skyrock...

Market Watch - 4 months ago

Shares of BioLine RX Ltd. soared 47% on heavy volume of 14.1 million shares in premarket trading Friday, after the Israel-based biopharmaceutical company announced positive interim results fro...

PRNewsWire - 4 months ago

TEL AVIV, Israel, Oct. 30, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today announced positive results fro...

PRNewsWire - 4 months ago

TEL AVIV, Israel, Oct. 29, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that the Company's l...

PRNewsWire - 6 months ago

TEL AVIV, Israel, Aug. 19, 2020 /PRNewswire/ -- BioLineRx Ltd.

Seeking Alpha - 6 months ago

BioLine RX Ltd (BLRX) CEO Philip Serlin on Q2 2020 Results - Earnings Call Transcript

PRNewsWire - 6 months ago

- On track to report three significant data readouts in next few months - - Completes successful financings, raising gross proceeds of $13.4 million; sufficient to reach multiple important mil...

PRNewsWire - 7 months ago

TEL AVIV, Israel, July 31, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, announced today it will release...

Zacks Investment Research - 7 months ago

BioLineRx (BLRX) will provide updates on its clinical programs when it releases second-quarter 2020 results.

Zacks Investment Research - 7 months ago

Inside the top-ranked stocks that have been exhibiting rising price-to-earnings ratios.

Other stocks mentioned: AVGR, PTI, VCNX, VIVE
Zacks Investment Research - 9 months ago

Top Ranked Momentum Stocks to Buy for May 29th

Other stocks mentioned: AXU, GSV, NTNX
PRNewsWire - 9 months ago

TEL AVIV, Israel, May 27, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical Company focused on oncology, today announced that a paper, entitle...

PRNewsWire - 9 months ago

TEL AVIV, Israel, May 26, 2020 /PRNewswire/ -- BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today announced that it has ente...

Seeking Alpha - 9 months ago

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q1 2020 Results - Earnings Call Transcript

PRNewsWire - 9 months ago

TEL AVIV, Israel, May 20, 2020 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage biopharmaceutical company focused on oncology, today reports its financial resu...

Seeking Alpha - 11 months ago

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

BioLineRx (BLRX) closes patient recruitment in the triple combination arm of the phase IIa COMBAT/KEYNOTE-202 study on Motixafortide to treat second-line metastatic pancreatic cancer.

Seeking Alpha - 1 year ago

How To Play BioLineRx In 2020

Zacks Investment Research - 1 year ago

The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.

Seeking Alpha - 1 year ago

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

BioLineRx (BLRX) starts dosing the first patient in the part 2 of the phase I/IIa study evaluating AGI-134 for solid tumors.

Seeking Alpha - 1 year ago

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

BioLineRx (BLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 1 year ago

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q1 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q4 2018 Results - Earnings Call Transcript

About BLRX

BioLineRx, a clinical-stage biopharmaceutical development company, focuses on oncology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of solid tumors, hematological malignancies, and stem cell mobilization; AGI-134, an immuno-oncology agent in the development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; ... [Read more...]

Industry
Biotechnology
IPO Date
Jul 25, 2011
CEO
Philip Serlin
Employees
38
Stock Exchange
NASDAQ
Ticker Symbol
BLRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for BioLineRx stock is "Buy." The 12-month stock price forecast is 11.33, which is an increase of 290.69% from the latest price.

Price Target
$11.33
(290.69% upside)
Analyst Consensus: Buy